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Abstract
Genistein has been shown to inhibit cancers both in vitro and in vivo, by altering the expression of several microRNAs
(miRNAs). In this study, we focused on tumor suppressor miRNAs regulated by genistein and investigated their function in
prostate cancer (PCa) and target pathways. Using miRNA microarray analysis and real-time RT-PCR we observed that miR-
574-3p was significantly up-regulated in PCa cells treated with genistein compared with vehicle control. The expression of
miR-574-3p was significantly lower in PCa cell lines and clinical PCa tissues compared with normal prostate cells (RWPE-1)
and adjacent normal tissues. Low expression level of miR-574-3p was correlated with advanced tumor stage and higher
Gleason score in PCa specimens. Re-expression of miR-574-3p in PCa cells significantly inhibited cell proliferation, migration
and invasion in vitro and in vivo. miR-574-3p restoration induced apoptosis through reducing Bcl-xL and activating caspase-
9 and caspase-3. Using GeneCodis software analysis, several pathways affected by miR-574-3p were identified, such as
‘Pathways in cancer’, ‘Jak-STAT signaling pathway’, and ‘Wnt signaling pathway’. Luciferase reporter assays demonstrated
that miR-574-3p directly binds to the 39 UTR of several target genes (such as RAC1, EGFR and EP300) that are components of
‘Pathways in cancer’. Quantitative real-time PCR and Western analysis showed that the mRNA and protein expression levels
of the three target genes in PCa cells were markedly down-regulated with miR-574-3p. Loss-of-function studies
demonstrated that the three target genes significantly affect cell proliferation, migration and invasion in PCa cell lines. Our
results show that genistein up-regulates tumor suppressor miR-574-3p expression targeting several cell signaling pathways.
These findings enhance understanding of how genistein regulates with miRNA in PCa.
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Introduction
The most commonly diagnosed type of cancer among men in
2012 is prostate cancer (PCa) that is expected to account for 29%
(241,740) of all new cancer cases. PCa ranks second to lung cancer
in cancer-related deaths and is expected to account for 9%
(28,170) of all male cancer deaths in 2012 [1]. Metastatic PCa is
not curable and continues to be the major cause of cancer deaths
[2]. Palliation can be achieved by hormone deprivation therapy
however after an excellent initial response, in approximately 2 to 3
years most of these PCas will relapse to the castration resistant
form of the disease [3] with death usually occurring within several
years [4]. There are no successful treatments for androgen-
independent PCa. A better understanding of biological mechan-
isms of androgen-independent PCa may lead to novel approaches
to treat unresponsive PCa more successfully.
Development of chemotherapeutic agents with low patient
toxicity is currently being investigated by many scientists. Many of
these agents are derived from natural plant products. Genistein is
a phytoestrogenic isoflavonoid that has pleiotropic biological
effects in a wide variety of cancers without any visible toxicity to
normal cells [5]. Genistein is a protein tyrosine kinase inhibitor
and affects cell proliferation, apoptosis, tumor angiogenesis,
metastasis and attenuates multidrug resistance involving key
components of signal transduction pathways [6,7,8].
microRNAs (miRNAs) are small non-coding RNAs (21–23
nucleotides) that mainly bind imperfectly to the 39 untranslated
region (UTR) of target mRNAs and negatively regulate gene
expression post-transcriptionally by translational repression and
degradation of target mRNA [9,10]. Since the identification of
miRNAs in 1993 over 1500 human miRNAs have been registered
in the miRBase database (http://microrna.sanger.ac.uk/). Bioin-
formatics indicate that more than 60% of protein-coding genes
may be targeted by miRNAs [11]. miRNAs play an important part
in many biological processes, such as development, differentiation,
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proliferation, apoptosis, angiogenesis and metabolism. In addition,
they are key regulators in many diseases including cancer [12] and
miRNAs may function as oncogenes or tumor suppressor genes
[13,14]. The effects of genistein on the regulation of several
miRNAs have been reported [15,16,17]. Our laboratory has
shown that genistein inhibits cancer cell growth targeting
oncogenic miRNAs such as miR-21, miR-151, miR-221 and
miR-222. In this study, we focused on tumor suppressor miR-574-
3p that is regulated by genistein and investigated its function in
PCa and target pathways.
Results
Genistein Treatment Increases miR-574-3p Expression
which is Down-regulated in PCa
To determine relative expression levels of miR-574-3p in
prostate cells, we performed quantitative real-time PCR using PC3
and DU145 cell lines and compared them with normal prostate
epithelial cells (RWPE-1). We observed that miR-574-3p expres-
sion was significantly down-regulated in PCa cell lines compared
to RWPE-1 cells (PC3 0.68-fold, DU145 0.65-fold) (Fig. 1A).
To identify miRNAs regulated by genistein, we conducted
a miRNA microarray using PC3 cells after genistein treatment
(Table 1). The expression of 33 miRNAs was significantly up-
regulated using two concentrations of genistein (25 mM and
50 mM) with miR-574-3p being the most affected. Previous
miRNA expression studies from our lab also showed that miR-
574-3p was significantly down-regulated in PCa samples com-
pared with non-cancerous prostate tissues [18]. To confirm
expression of miR-574-3p, we performed TaqMan quantitative
real-time PCR analysis and observed that miR-574-3p expression
was significantly up-regulated with genistein treatment (1.31 to
1.50-fold) (Fig. 1B).
miR-574-3p is Significantly Down-regulated in PCa Tissue
Specimens
We evaluated expression levels of miR-574-3p in human PCa
tissues (n = 48) and adjacent non-cancerous tissues (n = 48). The
expression level of miR-574-3p was significantly lower in PCa
compared with normal tissues (P,0.0001; Fig. 1C). To determine
if the levels of miR-574-3p in tumor tissues correlates with clinic-
pathological factors, we analyzed miR-574-3p expression levels in
human tumor samples. Clinical demographics of the study cohort
are summarized in Table 2. Correlation of 574-3p expression with
clinicopathological variables such as pathological stage (pT) and
Gleason score is shown in Fig. 1D. These results reveal that cases
with low miR-574-3p expression increase from low grade, low
pathological stage to high grade and high pathological stage.
Figure 1. Effect of genistein treatment and expression of miR-574-3p in PCa cells and specimens. (A) Expression of miR-574-3p in PCa
cell lines (DU145 and PC3) and normal prostate epithelial cells (RWPE-1). Real-time PCR showed that the expression levels of miR-574-3p were down-
regulated in PCa cell lines (DU145 and PC3). miR-574-3p expression was normalized to RNU48. Data are presented as mean 6 SE. *, P,0.05. (B)
Expression levels of miR-574-3p after treatment with genistein (25 mM and 50 mM). miR-574-3p expression increased by 30–50% in genistein treated
cells compared with controls. *, P,0.05. (C) miR-574-3p expression in clinical samples (Adjacent normal tissue, n = 48; PCa, n = 48). miR-574-3p
expression was determined by real-time PCR and normalized to RNU48. P,0.0001. (D) Real-time PCR showing correlation of clinicopathological
characteristics with miR-574-3p expression.
doi:10.1371/journal.pone.0058929.g001
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These results suggest that miR-574-3p is significantly down-
regulated in PCa and may be a putative tumor suppressor in PCa.
Effect of miR-574-3p Over-expression on Cell
Proliferation, Migration, and Invasion in PCa Cell Lines
in vitro and in vivo
To examine the functional roles of miR-574-3p, we performed
gain-of-function studies using a pre-miR-574-3p miRNA pre-
cursor transfected into PC3 and DU145 cells. The expression of
miR-574-3p was markedly up-regulated in Pre-miR miRNA
precursor transfectants (Fig. 2A; PC3 316.8-fold, DU145 307.5-
fold). Cell proliferation assay (MTS) and wound healing assay
showed significant inhibition in miR-574-3p transfectants in both
the PC3 and DU145 cells compared to the control transfectants
(Fig. 2B and 2C). Invasion assay (Matrigel) also showed that the
number of invading cells was significantly decreased in miR-574-
3p transfectants compared with their counterparts (Fig. 2D). To
confirm the effect of miR-574-3p on tumorigenicity in vivo, miR-
574-3p and miR-control-transfected DU145 cells were subcuta-
neously injected into nude mice. We observed that miR-574-3p
over-expression inhibited DU145 cell tumor formation in vivo
(Fig. 2E). These results suggest that miR-574-3p plays an
important role in tumor cell progression.
miR-574-3p Influences Cellular Apoptosis in PCa Cells
Since miR-574-3p restoration significantly inhibited cell pro-
liferation in PCa cell lines, we hypothesized that its restoration
may induce apoptosis. Fig. 3A and 3B showed that the apoptotic
and early apoptotic fractions (upper right and lower right in the
quadrant images, respectively) were greater in miR-574-3p
transfectants compared to control. This points to a pro-apoptotic
Table 1. Effect of genistein treatment for microRNA profiles in prostate cancer cells (PC3).
Normalized Intensity Ratio P value
non-treat 25 mM 50 mM 25 mM/non 50 mM/non Average 25 mM 50 mM
hsa-miR-574-3p 291.88 825.70 794.68 2.83 2.72 2.78 0.0000629 0.0000743
hsa-miR-29a 1839.50 3294.02 5835.99 1.79 3.17 2.38 0.0008651 0.0000297
hsa-miR-29b 1197.37 1878.11 4315.52 1.57 3.6 2.38 0.0031300 0.0000131
hsa-miR-1234 253.86 805.18 439.51 3.17 1.73 2.34 0.0000002 0.0000181
hsa-miR-4700-3p 190.06 474.90 346.86 2.5 1.83 2.14 0.0000049 0.0000504
hsa-miR-4732-3p 162.91 387.93 307.66 2.38 1.89 2.12 0.0001546 0.0001308
hsa-miR-5096 166.98 493.47 250.64 2.96 1.5 2.11 0.0000680 0.0090343
hsa-miR-1972 149.33 258.95 378.93 1.73 2.54 2.1 0.0000051 0.0000303
hsa-miR-3663-3p 162.91 343.96 323.10 2.11 1.98 2.05 0.0000210 0.0001064
hsa-miR-3194-5p 166.98 341.03 329.04 2.04 1.97 2.01 0.0000023 0.0001121
hsa-miR-4436b-5p 362.47 941.99 538.10 2.6 1.48 1.96 0.0000694 0.0012833
hsa-miR-3646 156.12 294.13 310.03 1.88 1.99 1.93 0.0000777 0.0000856
hsa-miR-3613-3p 153.40 364.48 239.95 2.38 1.56 1.93 0.0000190 0.0012331
hsa-miR-1203 115.39 220.84 217.38 1.91 1.88 1.9 0.0000648 0.0006706
hsa-miR-3679-3p 108.60 201.30 192.43 1.85 1.77 1.81 0.0004517 0.0021585
hsa-miR-1281 859.34 1674.86 1443.26 1.95 1.68 1.81 0.0000875 0.0010415
hsa-miR-4640-3p 153.40 297.06 244.70 1.94 1.6 1.76 0.0000244 0.0004460
hsa-miR-2467-3p 203.63 330.28 369.43 1.62 1.81 1.72 0.0006034 0.0000831
hsa-miR-484 224.00 428.00 320.72 1.91 1.43 1.65 0.0000459 0.0007682
hsa-miR-466 308.17 545.26 472.77 1.77 1.53 1.65 0.0002347 0.0016229
hsa-miR-29c 366.54 521.81 686.59 1.42 1.87 1.63 0.0007586 0.0001604
hsa-miR-1909* 107.25 170.03 174.62 1.59 1.63 1.61 0.0015811 0.0012480
hsa-miR-4440 177.84 259.93 313.60 1.46 1.76 1.61 0.0003777 0.0004528
hsa-miR-4252 131.68 188.59 226.88 1.43 1.72 1.57 0.0021412 0.0004876
hsa-miR-4312 207.71 322.46 327.85 1.55 1.58 1.57 0.0006465 0.0017571
hsa-miR-3189-5p 244.36 352.76 411.00 1.44 1.68 1.56 0.0000139 0.0000392
hsa-miR-4720-5p 122.18 193.48 186.50 1.58 1.53 1.55 0.0005705 0.0002532
hsa-miR-1226 154.76 241.36 237.57 1.56 1.54 1.55 0.0011385 0.0046299
hsa-miR-3619-3p 173.77 273.61 258.95 1.57 1.49 1.53 0.0001530 0.0014201
hsa-miR-4274 153.40 222.79 243.51 1.45 1.59 1.52 0.0028863 0.0030237
hsa-miR-760 271.51 421.16 396.75 1.55 1.46 1.51 0.0005929 0.0003805
hsa-miR-214 135.76 209.11 192.43 1.54 1.42 1.48 0.0042072 0.0048627
hsa-miR-3935 139.83 199.34 212.63 1.43 1.52 1.47 0.0000086 0.0050444
doi:10.1371/journal.pone.0058929.t001
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role for miR-574-3p and suggests that it affects apoptotic pathways
and regulates tumorigenicity. Therefore we examined the expres-
sion of various apoptotic proteins by Western blot analysis and
found that miR-574-3p re-expression causes Bcl-xL down-
regulation (Fig. 3C). Also, cleaved caspases-9 and -3 were up-
regulated (Fig. 3C), further supporting the fact that miR-574-3p is
a pro-apoptotic miRNA.
Search for miR-574-3p Target Genes by in silico Analysis
To search for putative target genes of miR-574-3p, we used the
TargetScan database. This program showed that miR-574-3p has
437 predicted target genes. We used in silico analysis to identify
the biological processes or pathways potentially regulated by miR-
574-3p. The candidate target genes were assigned to pathways
using GeneCodis software analysis (http://genecodis.cnb.csic.es)
[19,20,21], and statistically enriched pathways were identified
such as ‘Pathways in cancer’, ‘Jak-STAT signaling pathway’, and
‘Wnt signaling pathway’ (P,0.05, Table 3). We then performed
gene expression analyses for all candidate target genes involved in
each of the 9 pathways using microarray expression data, which
were approved by the Gene Expression Omnibus (GEO) and
focused on the ‘Pathways in cancer’. From this analysis, several
crucial gene targets were identified, including tropomyosin 3
(TPM3), wingless-type MMTV integration site family, member 5A
(WNT5A), ras-related C3 botulinum toxin substrate 1 (rho family,
small GTP binding protein Rac1) (RAC1), epidermal growth
factor receptor (EGFR), retinoid X receptor, alpha (RXRA), v-akt
murine thymoma viral oncogene homolog 2 (AKT2), and E1A
binding protein p300 (EP300).
Luciferase Reporter Assays Using Vectors Containing
39UTR Binding Sites of Putative Target Genes
To confirm the binding of miR-574-3p to the 39 UTR of these 7
target genes, we performed luciferase reporter assays. Each target
has one predicted binding site for miR-574-3p (Fig. 4A). We
cloned the putative miR-574-3p 39UTRs target into a luciferase
reporter assay vector. Luciferase reporter assays demonstrated that
miR-574-3p decreased the relative luciferase activities of RAC1,
EGFR and EP300 (Fig. 4B) except for other four genes. Mutation
of the putative miR-574-3p binding sites in these 39UTRs
decreased the response to miR-574-3p indicating that miR-574-
3p binds directly to the 39UTRs of RAC1, EGFR and EP300.
Regulation of Target Gene Expression in PCa Cell Lines by
miR-574-3p
Quantitative real-time PCR analysis showed that the mRNA
expression levels of the three target genes in PC3 and DU145 were
repressed in the miR-574-3p transfectants compared with the
controls (Fig. 4C). The protein expression levels of the three target
genes were also decreased in the miR-574-3p transfectants
compared with the controls (Fig. 4D).
Effect of Target Gene siRNA Knockdown on Cell
Proliferation, Migration, and Invasion Activity in PCa Cell
Lines
To examine the functional role of the target genes, we
performed loss-of-function studies using si-RNA knockdown with
PC3 and DU145 cells. The mRNA and protein expression of
RAC1, EGFR and EP300 were markedly repressed in si-RNA
transfectants compared to controls (Fig. 5A and 5B). Cell
proliferation assay (MTS) and wound healing assay showed
significant inhibition in si-RAC1, si-EGFR and si-EP300 transfec-
tants in both PC3 and DU145 cells compared to the control
transfectants (Fig. 5C and 5D). Invasion assay (Matrigel) also
showed that the number of invading cells was significantly
decreased in si-RAC1, si-EGFR and si-EP300 transfectants
compared with their control counterparts (Fig. 5E).
Discussion
Many studies have shown that genistein regulates cancer cell
proliferation, invasion, angiogenesis and metastasis by targeting
several genes and signaling pathways [6,7,22]. For example
genistein inhibited cell invasion reducing expression of MMP2
and MMP9 in human prostate epithelial and metastatic cells
where tumor progression is positively correlated with the
expression of MMP [23,24,25]. We have previously shown that
genistein down-regulated the expression of MCM2 by increasing
miR-1296 expression in PCa cells [26]. We have also reported that
genistein down-regulated miR-221/222 expression in PCa cells
resulting in increased expression of tumor suppressor gene ARHI
which is target of miR-221/222 [16]. Genistein has also been
reported to inhibit PCa angiogenesis by suppression of VEGF-
mediated autocrine and paracrine signaling pathways between
tumor cells and vascular endothelial cells [27]. The EP300 gene
has been identified as a co-activator of HIF1A and plays a role in
stimulation of hypoxia-induced genes such as VEGF [28]. RAC1
is also an important regulator of VEGF-mediated angiogenesis
[29] and miR-151 has an oncogenic function regulating activation
of RAC1 by targeting ARHGDIA [30]. We also recently
demonstrated that genistein inhibited PCa cell migration and
up-regulated several tumor suppressor genes including ARHGDIA
targeted by miR-151. In this study, we found that genistein up-
regulated miR-574-3p expression in PCa cells. In silico analysis
and luciferase reporter assays demonstrated that RAC1 and
EP300 were putative target genes for miR-574-3p. Quantitative
real-time PCR and Western analysis showed that mRNA and
protein expression levels of RAC1 and EP300 in PCa cells were
Table 2. Prostate cancer patient information.
Characteristics (%)
Age (years)
Median (range) 62 (47–81)
PSA (ng/ml)
Median (range) 7.0 (0.2–90)
Total number 48 (100.0)
Gleason Score
GS 6 23 (47.9)
GS 7 15 (31.3)
GS 8 6 (12.5)
GS 9 3 (6.2)
unknown 1 (2.1)
Pathological tumor stage
pT2a 8 (16.7)
pT2b 10 (20.8)
pT2c 13 (27.1)
pT3a 8 (16.7)
pT3b 1 (2.1)
unknown 8 (16.7)
Abbreviations: PSA = prostate-specific antigen; GS =Gleason Score.
doi:10.1371/journal.pone.0058929.t002
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Figure 2. Effect of miR-574-3p overexpression on PCa cell proliferation, migration and invasion in vitro and in vivo. (A) miR-574-3p
expression levels in PCa cell lines (PC3 and DU145) were determined by real-time PCR at 72 hours after transfection of Pre-miR miRNA precursor. miR-
574-3p expression was normalized to RNU48. Data are presented as the mean 6 SE. (B) Overexpression of miR-574-3p significantly inhibits cell
viability. Cell viability was analyzed by the MTS cell proliferation assay 1, 2 and 4 days after transient transfection. *, P,0.05. (C) Over-expression of
miR-574-3p significantly inhibits cell migration. After transfection (48 hours), a wound was formed by scraping and measured after 6, 12 and 24 hours.
Representative images of wound healing assay are shown at 2006magnification. **, P,0.0001. *, P,0.005. (D) Over-expression of miR-574-3p
significantly decreased cell invasion. Representative images of invasion assay are shown at 2006magnification. *, P,0.005. (E) Representative images
of tumors in nude mice 5 weeks after subcutaneous injection of transfected miR-574-3p DU145 cell lines or control cell lines and time course of tumor
growth.
doi:10.1371/journal.pone.0058929.g002
Figure 3. Effect of miR-574-3p overexpression on apoptosis. (A) Apoptosis assay using flow cytometry. Representative quadrant figures of
miR-control and miR-574-3p transfectants in PC3 (upper) and DU145 (lower) cells. (B) The bar chart indicates the ratio of apoptotic cell fractions (early
apoptotic plus apoptotic cells) in miR-574-3p transfectants compared with controls. Data for the apoptotic cell fractions are expressed as the relative
value for the average expression of the miR-control transfectant. *, P,0.05. (C) Immunoblots analysis for apoptotic markers in miR-control and miR-
574-3p transfected DU145 cells. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0058929.g003
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markedly down-regulated by miR-574-3p. Therefore genistein
may down-regulate RAC1 and EP300 by up-regulating miR-574-
3p.
Over-expression of Notch1 leads to induction of the EMT
phenotype and increased expression of miR-21 [31]. Genistein has
been shown to inactivate Notch and hedgehog signaling [31,32]
and we previously reported that genistein inhibited tumor cell
growth by reducing miR-21 expression in renal cell carcinoma
[15]. Thus genistein has a tumor suppressor function, regulating
‘Notch signaling’ by down-regulation of miR-21. Genistein can
also reduce cell proliferation by regulating ‘Wnt signaling’
[33,34,35] through miR-574-3p in cancer. In this study EGFR,
a putative target gene for miR-574-3p, was up-regulated in PCa
and increased in advanced cancer [36,37]. EGFR expression was
correlated with a high Gleason score, disease relapse and
hormone-refractory status [37,38]. Researchers have reported
that EGFR is regulated by several miRNAs such as miR-7, miR-
128b, miR-133, miR-145, miR146a, miR-146b-5p, miR-331-3p,
miR-542-5p [39–47]. Genistein up-regulated miR-146a expres-
sion in pancreatic cancer cells and functions as a tumor suppressor
in castration-resistant PCa [44,45]. Genistein might down-
regulated EGFR levels by up-regulating miR-574-3p.
Genistein induces apoptosis by regulating intrinsic and extrinsic
signaling pathways. Pro- and anti-apoptotic Bcl-2 family proteins
play a crucial role in regulating the mitochondrial apoptotic
pathway [48] and down-regulation of Bcl-xL by genistein induces
apoptosis in PCa cells [49]. In this pathway activated caspase-9
accelerates executioner caspase activation, including caspase-3,
and successively cleaves signaling molecules and cellular proteins
[49,50]. In our study, miR-574-3p induced apoptosis and
regulated expression of Bcl-xL, caspase-9 and caspase-3. There-
fore this study shows that genistein induced apoptosis in PCa cells
occurs by increased miR-574-3p expression.
In this study, we focused on miR-574-3p that was up-regulated
by genistein and was a significantly down-regulated miRNA
specific to PCa in the miRNA profile [18]. Our previous studies
indicated that miR-574-3p might be a tumor suppressor miRNA
in PCa and bladder cancer [18,51,52]. miR-574-3p is located on
chromosome 4p14, a frequently deleted chromosomal region in
PCa and bladder cancer cell lines [51,53]. Su et al reported that
the expression of miR-574-3p was reduced in gastric cancer and
cell proliferation, migration and invasion were significantly
inhibited in miR-574-3p-transfected gastric cancer cells [54].
They found the CUL2 gene to be a target of miR-574-3p using by
computational prediction and experimental validation. Our pre-
vious study demonstrated that miR-574-3p has tumor suppressor
function and that the oncogenic MESDC1 gene is targeted by
miR-574-3p in bladder cancer [52]. In this study, we have
demonstrated that miR-574-3p is down-regulated in clinical PCa
samples and androgen-independent PCa cell lines (PC3 and
DU145). Down-regulation of miR-574-3p expression in tumors is
related to high tumor stage and Gleason score indicating that
miR-574-3p may be used as a biomarker for tumor progression in
PCa.
In conclusion, our results show that genistein up-regulates miR-
574-3p expression which targets several cell signaling pathways.
These findings enhance our understanding of how genistein
regulates miRNA expression in PCa.
Materials and Methods
Clinical Prostate Specimens
All tissue slides were reviewed by a board certified pathologist
for the identification of PCa foci as well as adjacent normal
glandular epithelium. All cancer patients had elevated levels of
prostate specific antigen (PSA) and had undergone radical
Table 3. Pathways regulated by the putative target genes of miR-574-3p.
Number of
Genes Pathway ID KEGG Pathway p-value Gene Symbol
13 (KEGG) 05200 Pathways in cancer 0.0122 IL6,COL4A4,KITLG,CUL2,WNT7B,
BIRC5,TPM3,EP300,EGFR,WNT5A,
RAC1,RXRA,AKT2
10 (KEGG) 04020 Calcium signaling pathway 0.0112 CAMK2B,ATP2A2,CAMK2A,HTR7,
PTGER3,GNAQ,SLC25A4,EGFR,
PTAFR,ATP2B3
10 (KEGG) 04060 Cytokine-cytokine receptor interaction 0.0307 IL6,KITLG,IL28RA,BMPR2,EGFR,
LEP,OSMR,ACVR2B,ACVR1B,IL2RB
9 (KEGG) 05016 Huntington’s disease 0.0171 NDUFA4L2,CLTC,POLR2L,POLR2E,
CREB5,EP300,GNAQ,SLC25A4,HIP1
8 (KEGG) 04630 Jak-STAT signaling pathway 0.0174 IL6,IL28RA,SOCS4,EP300,LEP,
OSMR,IL2RB,AKT2
8 (KEGG) 04310 Wnt signaling pathway 0.0175 PRICKLE2,CAMK2B,WNT7B,
CAMK2A,EP300,WNT5A,RAC1,NKD1
7 (KEGG) 04916 Melanogenesis 0.0172 CAMK2B,KITLG,WNT7B,CAMK2A,
EP300,GNAQ,WNT5A
7 (KEGG) 04360 Axon guidance 0.0245 EPHA8,DPYSL2,ABLIM2,PLXNA2,
RAC1,RGS3,EPHB3
5 (KEGG) 04664 Fc epsilon RI signaling pathway 0.0456 MAPK11,SYK,RAC1,LAT,AKT2
doi:10.1371/journal.pone.0058929.t003
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prostatectomy from 1998 to 2004. The patient’ demographics are
shown in Table 2. Written informed consent was obtained from all
patients and the study was approved by the UCSF Committee on
Human Research (Approval number: H9058-35751-01).
Cell Culture
Human PCa cell lines, PC3 and DU145 and a non-malignant
epithelial prostate cell line, RWPE-1, were purchased from The
American Type Culture Collection (Manassas, VA, USA). PCa
cell lines were cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) in a humidified atmosphere of 5%
CO2 and 95% air at 37uC. RWPE-1 cells were cultured in
keratinocyte growth medium supplemented with 5 ng/mL human
recombinant epidermal growth factor and 0.05 mg/mL bovine
pituitary extract (Invitrogen, Carlsbad, CA, USA). Subconfluent
cells (60%–70% confluent) were treated with genistein (25 mmol/L
and 50 mmol/L; Sigma, St Louis, MO, USA) dissolved in
dimethylsulfoxide and cells treated with vehicle (dimethylsulfoxide)
served as control. Media and genistein were changed every day
and cells were grown for 4 days.
RNA Extraction
RNA was extracted from FFPE human samples using
a miRNeasy formalin-fixed paraffin-embedded kit (Qiagen,
Valencia, CA, USA) after microdissection. To digest DNA, the
Qiagen RNase-Free DNase kit was used. Total RNA was also
extracted from PCa cell lines and a non-malignant epithelial
prostate cell line using a miRNeasy mini kit (Qiagen) according to
the manufacturer’s instructions.
microRNA Microarray
For miRNA microarray, total RNA was extracted from PC3
cells treated with genistein using a miRNeasy Mini Kit. The
miRNA microarray analysis was carried out and analyzed by
a commercial company (Phalanx Biotech, Belmont, CA, USA)
using the human v3 miRNA OneArray platform that is designed
to contain 100% of miRBase Sequence Database Release 17.0.
Quantitative Real-time PCR
Extracted total RNA was reverse transcribed into single-
stranded cDNA using an iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA) and a TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR analysis was performed with an
Applied Biosystems Prism7500 Fast Sequence Detection System
using TaqMan universal PCR master mix according to the
manufacturer’s protocol (Applied Biosystems). Levels of RNA
expression were determined using the 7500 Fast System SDS
software version 1.3.1 (Applied Biosystems). PCR parameters for
cycling were as follows: 95uC for 20 seconds, 40 cycles of PCR at
95uC for 3 seconds, and 60uC for 30 seconds. All reactions were
done in a 10-mL reaction volume in triplicate. The data were
analyzed with the delta-delta Ct method to calculate the fold-
change. TaqMan probes and primers for RAC1 (assay ID:
Hs01902432_s1), EGFR (assay ID: Hs01076078_m1), EP300
(assay ID: Hs00914223_m1), GAPDH (assay ID:
Hs02758991_g1), miR-574-3p (assay ID: 002349), RNU48 (Assay
ID: 001006) were obtained from Applied Biosystems. GAPDH
and RNU48 were used as internal controls.
Western Analysis
At 72 hours after transfection, cells were lysed with RIPA buffer
(Pierce, Brebieres, France) containing protease inhibitors (Sigma).
Protein quantification was done using a BCA protein assay kit
(Pierce). Protein lysate (30 mg) was separated on 4% to 20% SDS
polyacrylamide gels and transferred to a PVDF membrane.
Antibodies to EP300 and Bcl-xL were purchased from Invitrogen
and Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
bodies against RAC1, EGFR and GAPDH were purchased from
GeneTex (Irvine, CA, USA) respectively. Antibodies to cleaved
caspase-3, -9 and caspase-3, -9 were purchased from Cell
Signaling Technology (Danvers, MA, USA). After incubation
with primary antibody the membrane was washed and then
incubated with secondary antibodies conjugated to horseradish
peroxidase (Cell Signaling Technology, Danvers, MA, USA).
Specific complexes were visualized with an echochemilumines-
cence (ECL) detection system (GE Healthcare, Little Chalfont,
UK). The membrane was stripped using ReBlot Plus Strong
Antibody Stripping Solution (Millipore, Billerica, MA, USA). The
expression level of genes was then evaluated by using ImageJ
software (ver. 1.43; http://rsbweb.nih.gov/ij/index.html).
Transfection
Pre-miR miRNA precursor and negative control (Applied
Biosystems) were used in the gain-of-function experiments.
RAC1, EGFR and EP300 siRNA (Sigma) and negative control
siRNA (D-001810-10; Thermo Fisher Scientific, Waltham, MA,
USA) were used in the loss-of-function experiments. PC3 and
DU145 cells were transiently transfected using Lipofectamine
2000 transfection reagent (Invitrogen), according to the manu-
facturer’s recommendations.
Cell Proliferation, Migration, and Invasion Assays
Cell proliferation was measured using a CellTiter 96 AQueous
One Solution Cell Proliferation Assay (MTS) (Promega, Madison,
WI, USA) performed according to the manufacturer’s instructions.
Cell proliferation was determined by absorbance measurements at
490 nm using SpectraMAX 190 (Molecular Devices Co.,
Sunnyvale, CA, USA). Cell migration activity was evaluated by
a wound-healing assay. Cells were plated in six-well dishes, and the
cell monolayers were scraped using a P-20 micropipette tip. The
width of the initial gap (0 h) and the residual gap 6, 12 and 24
hours after wounding were calculated from photomicrographs. A
cell invasion assay was carried out using modified Boyden
Chambers consisting of transwell-precoated Matrigel membrane
filter inserts with eight micron pores in 24-well tissue culture plates
(BD Biosciences, Bedford, MA, USA). Minimum essential medium
containing 10% FBS in the lower chamber served as the
chemoattractant, as described previously [55]. All experiments
were performed in triplicate.
Figure 4. miR-574-3p targets RAC1, EGFR, EP300. (A) Putative miR-574-3p binding and mutated sites in the 39UTR of target genes. (B)
Luciferase reporter assays using vectors encoding putative 39UTR binding sites. PC3 and DU145 cells were transiently transfected with Pre-miR miRNA
precursor or negative control, followed by transient transfection with basic vector or wild-type 39UTR reporter plasmids or mutated 39UTR plasmids
for 24 hours. 39UTR reporter activity was measured by luciferase assay and normalized to the activity of Renilla luciferase. Data are presented as the
mean 6 SE. *, P,0.05. (C). The mRNA levels of the three target genes of miR-574-3p were determined by quantitative real-time PCR analyses after
transfection with miR-574-3p mimics and negative control in PCa cell lines (PC3 and DU145). *, P,0.05. (D) Immunoblot analysis for target genes in
miR-control and miR-574-3p transfected PC3 cells. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0058929.g004
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In vivo Tumor Growth
All animal care was in accordance with the guidelines of the San
Francisco Veterans Affairs Medical Center and the study was
approved by the San Francisco VA IACUC (Protocol number: 11-
008-01). Animal users have completed training programs to
handle and work with mice through AALAS (American Associ-
ation for Laboratory Animal Science) prior to animal experiments.
For the subcutaneous xenograft mouse model, DU145 cells
(2.56106) that were transiently transfected with miR-574-3p or
miR-control were suspended in 50 mL RPMI 1640 medium and
were subcutaneously injected into female nude mice (strain
BALB/c nu/nu; Charles River Laboratories, Inc., Wilmington,
MA, USA, 5 weeks old). A total of 8 nude mice (4-miR-574-3p, 4-
miR-control) were used and tumor growth was examined over the
course of 35 days. Tumor volume was calculated on the basis of
width (x) and length (y): x2y/2, where x,y.
Apoptosis Assays
Fluorescence-activated cell-sorting (FACS) analysis for apoptosis
was done 96 hours post-transfection, using Annexin V-FITC/7-
AAD Kit (Beckman Coulter, Brea, CA, USA), according to the
manufacturer’s protocol. Stained cells were immediately analyzed
with a flow cytometer (Cell Lab Quanta SC; Beckman Coulter).
Identification of miR-574-3p Regulated Target Genes and
Bioinformatic Analysis
To search for genes regulated by miR-574-3p, we used
TargetScan algorism (release 6.2, http://www.targetscan.org/).
To identify the biological processes or pathways potentially
regulated by miR-574-3p, we performed GeneCodis analysis
(http://genecodis.dacya.ucm.es/) using all of the candidate genes.
Then, to identify networks among the miRNAs and their target
genes, we analyzed and characterized those genes in KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway categories.
These data were used to examine miRNA-regulated molecular
networks in human cells. We performed gene expression analyses
of all candidate genes involved in each of the pathways using
microarray expression data approved by the GEO and were
assigned GEO accession numbers (GSE29079). In the Affymetrix
Human Exon 1.0 ST Array (Affymetrix, Santa Clara, CA, USA)
datasets, we examined 47 PCa tissues and 47 normal prostate
tissues, all of which were collected from patients who had not been
exposed to neo-adjuvant radio-, cytotoxic- or endocrine therapy
before the operation. The data was normalized and analyzed with
the GeneSpring (Agilent Technologies, Santa Clara, CA, USA).
Statistical analyses were conducted using the Mann Whitney U-
test with cut-off P,0.05.
Plasmid Construction and Dual-luciferase Reporter
Assays
For 39 UTR luciferase reporter assay, PmirGLO Dual-
Luciferase miRNA Target Expression Vector was used (Promega).
The oligonucleotide sequences (wild-type) used are shown in Table
S1. We also constructed mutated oligonucleotides for each of the
wild-type oligonucleotides (Table S1). In a total volume of 25 ml,
1 ml each of 100 mM forward and reverse oligonucleotide, 2.5 ml
of 106 annealing buffer (100 mM Tris–HCl, pH 7.5, 1 M NaCl
and 10 mM ethylenediaminetetraacetic acid) and 20.5 ml water
were incubated at 95uC for 3 min and then placed at 37uC for
15 min. The oligonucleotides were ligated into the PmeI–XbaI site
of pmirGLO Dual-Luciferase miRNA Target Expression Vector.
For 39 UTR luciferase assay, PCa cells were co-transfected with
Pre-miR miRNA precursor and pmirGLO Dual-Luciferase
miRNA Target Expression Vectors using Lipofectamine 2000
(Invitrogen) and X-tremeGENE HP DNA Transfection Reagent
(Roche Diagnosis, Basel, Switzerland, USA) according to the
manufacturer’s instructions. Luciferase reporter assay was per-
formed using the Dual-Luciferase Reporter Assay System
(Promega) 24 hours after transfection. Firefly luciferase activities
were normalized with Renilla luciferase. We also included basic
vector containing no insert as a mock control.
Statistical Analysis
The relationship between two variables and the numerical
values obtained by real-time RT-PCR were analyzed using the
nonparametric Mann-Whitney U test. All analyses were per-
formed using Expert StatView (version 4, SAS Institute Inc., Cary,
NC, USA). Data are shown as mean values 6 standard error. P
values of ,0.05 were regarded as statistically significant.
Supporting Information
Table S1 Primer oligonucleotide sequences (wild-type
and mutated).
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